Premium
Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication
Author(s) -
YANG H.B.,
CHENG H.C.,
SHEU B.S.,
HUNG K.H.,
LIOU M.F.,
WU J.J.
Publication year - 2007
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.03224.x
Subject(s) - medicine , helicobacter pylori , celecoxib , intestinal metaplasia , gastroenterology , helicobacter infections , metaplasia , gastritis
Summary Background and Aim To test whether the chronic users of celecoxib, a selective cyclo‐oxygenase‐2 inhibitor, had less Helicobacter pylori ‐related intestinal metaplasia or if such users’ intestinal metaplasia could be prone to disappear after H. pylori eradication. Methods The study enrolled 150 chronic celecoxib users and 216 non‐users who underwent pan‐endoscopy to detect H. pylori infection and its related intestinal metaplasia. One hundred and three H. pylori ‐infected patients with intestinal metaplasia (43 chronic celecoxib users and 60 non‐users) received anti‐ H. pylori therapy and completed the 12‐month follow‐up to survey the regression of intestinal metaplasia by mean intestinal metaplasia score. Results There were no differences in the prevalence of H. pylori ‐related intestinal metaplasia between the chronic celecoxib users and controls ( P > 0.05). On the 12th month of follow‐up, chronic celecoxib users had a lower mean intestinal metaplasia score (1.2 vs. 1.8, P < 0.005) and a higher regression rate of intestinal metaplasia (42% vs. 20%, P = 0.027) than non‐users. Conclusions With H. pylori infection, chronic celecoxib users still showed limited effects to decrease intestinal metaplasia. Nevertheless, celecoxib should be promising to assist H. pylori eradication for the control of gastric intestinal metaplasia and cancer risk.